Popular Articles

Mar 01, 2012
Pharmaceutical Executive
By Pharmaceutical Executive Editors
Our annual press audit finds that the big news in 2011 for pharma was ... no news.
Jan 01, 2012
Pharmaceutical Executive
Pharma has become unusually quick to strike embrace the iPad. But the industry's inherent conservatism means it has some way to go to fully milk the device's potential.
Jan 01, 2012
Pharmaceutical Executive
By Pharmaceutical Executive Editors
The challenge for 2012 is that many new treatments may not complete the move from 'bench to bedside' in time to plug the yawning revenue gap.
Jan 01, 2012
Pharmaceutical Executive
A selection of the recent breakthrough technologies showcased at the Cleveland Clinic's Medical Innovations Summit.
Jan 01, 2012
Pharmaceutical Executive
By Pharmaceutical Executive Editors
It's a disturbing irony: In an industry whose entire economic value is founded on its ability to innovate, why is there so much discomfort with the risk required for innovation. Where did the courage to innovate go?
Dec 01, 2011
Pharmaceutical Executive
By Pharmaceutical Executive Editors
It's a neck and neck race toward safer, faster, and medically superior treatments. Which organizations have what it takes to jockey their products into the winner's circle?
Sep 01, 2011
Pharmaceutical Executive
Despite the gloom, most forecasts show the US will stay atop the industry in profits for at least the next generation of products.
Sep 01, 2011
Pharmaceutical Executive
By Pharmaceutical Executive Editors
Especially when payers come to the table holding the best cards — leaving industry second-guessing its strategy.
Sep 01, 2011
Pharmaceutical Executive
The time is right for industry to overcome its social media phobia once and for all.
Jul 01, 2011
Pharmaceutical Executive
Taking Onyx Pharmaceuticals to new heights—CEO Tony Coles talks to PharmExec about the midsize company's transition from adolescence to adulthood.
native1_300x100
lorem ipsum